Jubilant Pharmova Limited

Jubilant Pharmova Limited (JUBLPHARMA) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

jubilantpharmova.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-09-03

Stock price
₹907.90
Market cap
14,369 Cr
Stock P/E
50.0
P/B
2.02
Dividend yield
0.6%

Sign in for full ratios and TTM. Learn about these metrics →

Share price

NSE closing price from historical market data.

Loading price history…

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales1,680 Cr1,677 Cr1,759 Cr1,732 Cr1,752 Cr1,822 Cr1,929 Cr1,901 Cr1,966 Cr2,123 Cr2,290 Cr2,229 Cr
Operating expenses (approx.)1,439 Cr1,459 Cr1,487 Cr1,480 Cr1,463 Cr1,534 Cr1,583 Cr1,611 Cr1,625 Cr1,833 Cr1,951 Cr1,981 Cr
EBITDA242 Cr218 Cr271 Cr252 Cr289 Cr287 Cr345 Cr290 Cr341 Cr290 Cr339 Cr248 Cr
OPM %14.4%13.0%15.4%14.5%16.5%15.8%17.9%15.2%17.4%13.6%14.8%11.1%
Other income10 Cr36 Cr14 Cr14 Cr22 Cr9 Cr12 Cr12 Cr10 Cr21 Cr24 Cr20 Cr
Interest66 Cr71 Cr73 Cr71 Cr61 Cr56 Cr53 Cr49 Cr50 Cr56 Cr57 Cr54 Cr
Depreciation97 Cr95 Cr101 Cr91 Cr91 Cr91 Cr95 Cr98 Cr105 Cr121 Cr117 Cr127 Cr
Profit before tax98 Cr101 Cr-54 Cr500 Cr144 Cr131 Cr206 Cr154 Cr190 Cr93 Cr176 Cr86 Cr
Tax %36.6%34.3%-15.1%3.6%29.0%22.8%26.6%33.6%37.0%40.3%32.2%34.7%
Net profit62 Cr66 Cr-62 Cr482 Cr103 Cr101 Cr151 Cr103 Cr120 Cr56 Cr119 Cr56 Cr
EPS (₹)₹3.94₹4.22₹-3.69₹30.44₹6.47₹6.37₹9.71₹6.49₹7.59₹3.52₹7.55₹3.57

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales9,111 Cr9,154 Cr6,099 Cr6,059 Cr6,282 Cr6,703 Cr7,235 Cr8,280 CrSign in for TTM
Operating expenses (approx.)7,372 Cr7,207 Cr4,702 Cr4,974 Cr5,505 Cr5,802 Cr6,061 Cr7,020 CrSign in for TTM
EBITDA1,739 Cr1,947 Cr1,396 Cr1,085 Cr776 Cr901 Cr1,174 Cr1,260 CrSign in for TTM
OPM %19.1%21.3%22.9%17.9%12.4%13.4%16.2%15.2%Sign in for TTM
Other income36 Cr47 Cr18 Cr82 Cr38 Cr69 Cr57 Cr66 CrSign in for TTM
Interest220 Cr287 Cr184 Cr145 Cr188 Cr272 Cr240 Cr212 CrSign in for TTM
Depreciation371 Cr462 Cr349 Cr382 Cr554 Cr382 Cr369 Cr440 CrSign in for TTM
Profit before tax904 Cr1,211 Cr1,201 Cr630 Cr28 Cr171 Cr981 Cr614 CrSign in for TTM
Tax %36.2%25.8%24.8%34.5%333.5%57.4%14.7%35.3%Sign in for TTM
Net profit577 Cr898 Cr836 Cr413 Cr-65 Cr73 Cr836 Cr398 CrSign in for TTM
EPS (₹)₹36.86₹56.39₹52.48₹26.00₹-3.83₹4.87₹52.99₹25.15Sign in for TTM
Dividend payout %———19.4%—109.8%9.5%20.0%Sign in for TTM
Sign in for TTM

Trailing twelve months totals and margin rows

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital16 Cr16 Cr16 Cr16 Cr16 Cr16 Cr16 Cr16 Cr
Reserves4,793 Cr5,588 Cr4,726 Cr5,303 Cr5,383 Cr5,418 Cr6,239 Cr7,077 Cr
Borrowings4,743 Cr———3,410 Cr3,414 Cr2,437 Cr3,220 Cr
Other liabilities1,917 Cr6,918 Cr4,177 Cr4,672 Cr2,355 Cr2,713 Cr4,081 Cr5,208 Cr
Total liabilities11,469 Cr12,522 Cr8,918 Cr9,991 Cr11,157 Cr11,549 Cr12,756 Cr15,523 Cr
Fixed assets (net)3,396 Cr———2,298 Cr2,158 Cr2,132 Cr3,510 Cr
CWIP492 Cr———773 Cr1,252 Cr2,715 Cr2,962 Cr
Investments115 Cr———256 Cr42 Cr44 Cr61 Cr
Loans & advances4 Cr———1 Cr0.80 Cr1 Cr2 Cr
Inventories1,417 Cr———1,381 Cr1,290 Cr1,129 Cr1,232 Cr
Trade receivables1,272 Cr———961 Cr916 Cr892 Cr1,070 Cr
Cash & bank1,005 Cr———1,014 Cr956 Cr1,088 Cr1,267 Cr
Other assets3,768 Cr12,522 Cr8,918 Cr9,991 Cr4,473 Cr4,934 Cr4,756 Cr5,420 Cr
Total assets11,469 Cr12,522 Cr8,918 Cr9,991 Cr11,157 Cr11,549 Cr12,756 Cr15,523 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity———838 Cr661 Cr971 Cr1,072 Cr1,227 Cr
Cash from investing———-380 Cr-544 Cr-608 Cr488 Cr-1,260 Cr
Cash from financing———-33 Cr-157 Cr-432 Cr-1,453 Cr95 Cr
Net cash flow———482 Cr30 Cr-57 Cr132 Cr179 Cr
Free cash flow (OCF − Capex)———238 Cr-154 Cr74 Cr-43 Cr-222 Cr

Ratios

Ratios as reported or derived per annual period.

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %11.8%26.7%29.2%14.6%2.5%5.0%14.1%8.0%
ROE %11.9%16.0%17.6%7.8%-1.1%1.4%13.5%5.6%
Debtor days51———56504547
Inventory days157———302258207193
Days payable113———179172184194
Cash conversion cycle95———1781376847
Debt / equity0.99—0.00—0.630.630.390.45
Current ratio2.19———2.121.921.621.62
Net debt / EBITDA2.150.000.000.003.092.731.151.55

Compare with peers

Loading peers…